Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy

Georgios Nteliopoulos, MSc, PhD, Alexandra Bazeos, MB, BS, MRCP, Gareth Gerrard, PhD, Simone Claudiani, MD, Ed Curry, PhD, Mary Alikian, MSc, PhD, Hui En Foong, Letizia Foroni, MD PhD FRCPath, Jane F. Apperley, MD

Blood (2016) 128 (22): 1223.

https://doi.org/10.1182/blood.V128.22.1223.1223

Published: 2016

Journal Articles

Target Enrichment and High-Throughput Sequencing of 80 Ribosomal Protein Genes to Identify Mutations Associated with Diamond-Blackfan Anaemia.

Gareth Gerrard, PhD, Mikel Valgañón, PhD, Hui En Foong, MSc, Dalia Kasperaviciute, PhD, Michael Müller, PhD, Laurence Game, PhD, Deena Iskander, MRCP, Irene Roberts, Letizia Foroni, MD, PhD, FRCPath, Josu de la Fuente, PhD, FRCP, MRCPCH, FRCPath, Anastasios Karadimitris, MD, PhD

Blood (2012) 120 (21): 2369.

https://doi.org/10.1182/blood.V120.21.2369.2369

Published: 2012

Journal Articles

Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

Timothy P Hughes, MD, Andreas Hochhaus, MD, Susan Branford, PhD, Martin C Müller, MD, Letizia Foroni, MD, PhD, FRCPath, Brian J. Druker, MD, François Guilhot, MD, Richard A. Larson, MD, Stephen G O’Brien, MD, PhD, Roger J. Waltzman, MD, Manisha Mone, PhD, Elisabeth Wehrle, PhD, Jerald P. Radich, MD, John M. Goldman, MD

Blood (2008) 112 (11): 334.

https://doi.org/10.1182/blood.V112.11.334.334

Published: 2008

Journal Articles

Common Submicroscopic Genomic Imbalances Accompany the Ph Chromosome at Diagnosis in Chronic Myeloid Leukemia

Jamshid S Khorashad, MD, Valeria A De Melo, Heike Fiegler, PhD, Gareth Gerrard, PhD, Dan Brudzevsky, PhD, David Marin, MD, Jane F. Apperley, MBChB, FRCP, FRCPath, John M Goldman, DM, FRCP, FRCPath, Letizia Foroni, MD, PhD, FRCPath, Alistair G Reid, PhD

Blood (2008) 112 (11): 3113.

https://doi.org/10.1182/blood.V112.11.3113.3113

Published: 2008

Journal Articles

WT1 and PRAME Expression in CML: Quantitation by Real-Time PCR and Correlation with BCR-ABL Expression Levels

Gareth Gerrard, PhD, Caroline Cloke, BSc, Ian H Gabriel, Dr, Katayoun Rezvani, MD, PhD, Jane F. Apperley, MBChB, FRCP, FRCPath, Letizia Foroni, MD, PhD, FRCPath

Blood (2008) 112 (11): 4225.

https://doi.org/10.1182/blood.V112.11.4225.4225

Published: 2008

NARROW

Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy

Target Enrichment and High-Throughput Sequencing of 80 Ribosomal Protein Genes to Identify Mutations Associated with Diamond-Blackfan Anaemia.

Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

Common Submicroscopic Genomic Imbalances Accompany the Ph Chromosome at Diagnosis in Chronic Myeloid Leukemia

WT1 and PRAME Expression in CML: Quantitation by Real-Time PCR and Correlation with BCR-ABL Expression Levels

Email alerts

ASH Publications

American Society of Hematology

Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy

Target Enrichment and High-Throughput Sequencing of 80 Ribosomal Protein Genes to Identify Mutations Associated with Diamond-Blackfan Anaemia.

Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

Common Submicroscopic Genomic Imbalances Accompany the Ph Chromosome at Diagnosis in Chronic Myeloid Leukemia

WT1 and PRAME Expression in CML: Quantitation by Real-Time PCR and Correlation with BCR-ABL Expression Levels

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only